$4.10
-5.9%Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
ZURA • NASDAQ
| Zura Bio Limited Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
109.4M | 176.5M | 99.8M | 1.6M | 729.2K | |
109.4M | 176.5M | 99.8M | 1.6M | 729.2K | |
0.0 | 0.0 | 0.0 | 19.7K | 422.9K | |
2.9M | 2.2M | 1M | 189.3K | 0.0 | |
112.3M | 178.7M | 100.8M | 1.8M | 1.2M | |
NON-CURRENT ASSETS | |||||
126K | 91K | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 139.4M | |
1.5M | 698K | 0.0 | 3.5M | 0.0 | |
1.6M | 789K | 0.0 | 3.5M | 139.4M | |
113.9M | 179.5M | 100.8M | 5.3M | 140.6M | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
0.0 | 733K | 2.7M | 2M | 0.0 | |
0.0 | 733K | 2.7M | 2M | 0.0 | |
0.0 | 0.0 | 16.4M | 2.3M | 0.0 | |
0.0 | 0.0 | 0.0 | 7.8M | 0.0 | |
12.4M | 18.8M | 1.2M | 2.8M | 272.3K | |
12.4M | 19.5M | 20.3M | 14.8M | 272.3K | |
NON-CURRENT LIABILITIES | |||||
0.0 | 0.0 | 990K | 12.5M | 10.1M | |
0.0 | 0.0 | 990K | 12.5M | 10.1M | |
12.4M | 19.5M | 21.3M | 27.3M | 10.4M | |
SHAREHOLDERS' EQUITY | |||||
7K | 7K | 4K | 0.0 | 139.4M | |
326.1M | 302.7M | 162.8M | 0.0 | 0.0 | |
-224.5M | -155.9M | -103.5M | -32.1M | -9.2M | |
101.5M | 146.8M | 59.3M | -32.1M | 130.2M | |
101.5M | 160M | 79.6M | -22.1M | 130.2M | |
0.0 | 13.2M | 20.2M | 10M | 0.0 | |
SUMMARY | |||||
113.9M | 179.5M | 100.8M | 5.3M | 140.6M | |
0.0 | 0.0 | 0.0 | 0.0 | 139.4M | |
0.0 | 0.0 | 0.0 | 7.8M | 0.0 | |
-109.4M | -176.5M | -99.8M | 6.2M | -729.2K | |
65,018,058 | 65,018,058 | 65,018,058 | 65,018,058 | 65,018,058 |
ZURA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 23, 2026 | April 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K/A 8-K/A 2026 (Amended) N/A | February 26, 2026 | February 24, 2026 | 2026 |
Continue your ZURA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.